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Abstract
Background: Patients diagnosed with melanoma frequently search the internet for treatment information, including novel and
complex immunotherapy. However, health literacy is limited among half of the German population, and no assessment of websites
on melanoma treatment has been performed so far.
Objective: The aim of this study was to identify and assess the most visible websites in German language on melanoma
immunotherapy.
Methods: In accordance with the common Web-based information-seeking behavior of patients with cancer, the first 20 hits
on Google, Yahoo, and Bing were searched for combinations of German synonyms for “melanoma” and “immunotherapy” in
July 2017. Websites that met our predefined eligibility criteria were considered for assessment. Three reviewers independently
assessed their quality by using the established DISCERN tool and by checking the presence of quality certification. Usability and
reliability were evaluated by the LIDA tool and understandability by the Patient Education Materials Assessment Tool (PEMAT).
The Flesch Reading Ease Score (FRES) was calculated to estimate the readability. The ALEXA and SISTRIX tools were used
to investigate the websites’ popularity and visibility. The interrater agreement was determined by calculating Cronbach alpha.
Subgroup differences were identified by t test, U test, or one-way analysis of variance.
Results: Of 480 hits, 45 single websites from 30 domains were assessed. Only 2 website domains displayed a German quality
certification. The average assessment scores, mean (SD), were as follows: DISCERN, 48 (7.6); LIDA (usability), 40 (2.0); LIDA
(reliability), 10 (1.6); PEMAT, 69% (16%); and FRES, 17 (14), indicating mediocre quality, good usability, and understandability
but low reliability and an even very low readability of the included individual websites. SISTRIX scores ranged from 0 to 6872
and ALEXA scores ranged from 17 to 192,675, indicating heterogeneity of the visibility and popularity of German website
domains providing information on melanoma immunotherapy.
Conclusions: Optimization of the most accessible German websites on melanoma immunotherapy is desirable. Especially,
simplification of the readability of information and further adaption to reliability criteria are required to support the education of
patients with melanoma and laypersons, and to enhance transparency.
(JMIR Cancer 2018;4(2):e10676)  doi: 10.2196/10676
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Introduction
Melanoma incidence has been increasing worldwide [1,2]. In
Germany, it accounts for about 4% of all cancer types and is
the fifth most common malignancy [3]. Approvals of new
effective therapies in the last decade have substantially expanded
the treatment spectrum, especially for patients with melanoma
and metastatic disease. One of these treatment options is
immunotherapy, the application of which has resulted in
pioneering response rates and markedly increased survival
chances of patients with melanoma [4-6].
Given the novelty, complexity, and potential toxicity of
immunotherapy, the need for educating patients with melanoma
has been increasing. Physicians serve as the primary information
source in this context. However, recent research suggests that
the information-seeking behavior of patients with melanoma
[7-9] and the resources they use have been changing alongside
with the application of modern media and structural changes in
health care provision. Besides medical consultations and written
information [10], as cancer patients’ persisting primary and
most important sources of health information, a growing
preference of the internet to acquire disease-specific information
has been observed [8-11]. The search engines Google, Bing,
and Yahoo are the most searched in this respect by the public
and patients [12-15]. However, although the internet becomes
increasingly popular, many patients with cancer are skeptical
of Web-based information [16,17]. Not all websites on cancer
issues are prepared by health professionals or medical and health
care authorities, and the reliability and accuracy of the
information available remain questionable [18]. Web-based
information for patients with melanoma was previously found
to be difficult to read [16], did not provide complete basic and
transparent information, or contained misinformation [19].
It has become a common practice to review the most visible
Web-based cancer information on therapy using scientifically
validated tools [20-24] to explore what shortcomings exist and
what should be considered when using the information.
Web-based treatment information is used by patients to support
their treatment decision making [25]. Therefore, genuine
information should be presented in a complete and simple
manner. The aim of this study was to explore first, what websites
with information on melanoma immunotherapy in German
language are currently visible and accessible at most when
applying common Web-based search engines, and then to assess
them in terms of their quality, reliability, usability,
understandability, readability, visibility, and popularity. The
results of this study will be beneficial for dermatologists to
recommend and for patients with melanoma to identify
appropriate websites with information on immunotherapy.
Moreover, the results will indicate potential issues that providers
should address to improve their websites.
Methods
Search Strategy
In accordance with common Web-based search patterns of the
general population, including patients with cancer [12-15], 2
independent researchers (JB and TS) searched the first 20 hits
on the most frequently used Web-based search engines Google,
Bing, and Yahoo for a combination of German synonyms for
“melanoma” and “immunotherapy.” A priori, Google trends
analysis was used to identify relevant search combinations that
people frequently used when searching Google for this topic.
The search terms were adapted according to the Google trends
analysis and were combined as “Melanom + Immuntherapie,”
“Malignes Melanom + Immuntherapie,” “Hautkrebs +
Immuntherapie,” and “Schwarzer Hautkrebs + Immuntherapie.”
The search was performed between July 10 and July 14, 2017,
using the Web-based browsers Internet Explorer version 11 or
Mozilla Firefox version 57.
Inclusion and Exclusion Criteria
To be eligible for assessment, websites had to meet the following
inclusion criteria: (1) contain information on immunotherapy
referring to melanoma; (2) contain at least 5 sentences of
information; (3) be accessible for free and for all users
(including patients and laypersons); and (4) information is
provided in German language. Websites were excluded if they
were solely patient exchange platforms, advertising websites,
conference or congress websites (eg, of medical conferences),
websites dealing with nonmelanoma skin cancer (NMSC),
websites about melanoma and NMSC in animals, websites solely
providing videos or images, and websites of restricted access
(eg, asking for log-in).
All hits of the search engine queries were screened for
duplicates, and the predefined eligibility criteria were applied.
Whenever discrepancies on the relevance of a website arose, a
third researcher (FM or CB) was consulted as arbiter for
resolution.
Grouping of Websites
Owing to the variability in the creators of websites and for
comparison, the websites were grouped by application of 2
different approaches, similar to Azer et al [20]. First, the
websites were grouped according to their providers as follows:
(1) commercial and pharmaceutical companies; (2)
noncommercial or charity providers; (3) medical or scientific
providers; (4) general public press; (5) commercial health
information services; (6) clinics or health professionals; and (7)
Wikipedia.org. The categorization was conducted independently
by 2 researchers (JB and TS); disagreements were discussed
and remedied in a subsequent meeting. Second, the groups
(1)-(3) and (6) were summarized as oncology expert domains,
and the groups (4), (5), and (7) were summarized as domains
provided by the general public press. “General public press”
domains describe domains that do not primarily address a
particular subgroup of users, such as patients or medical experts,
but the general public; these are usually provided by media such
as news magazines, tabloids, and radio or television channels.
Data Management and Website Assessment
The available baseline information (URL, title, name of the
website provider, and year of publication) of each included
website was documented. For inaccessible information, the tool
Whois Lookup was used to complete the data collection.
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Assessment was performed on the individual website level and
the domain level, depending on the assessment tool.
Three reviewers (JB, TS, and LR) independently assessed the
websites’ quality of information, usability, reliability, and
understandability by applying different validated tools. Prior to
the final assessment of the websites, the 3 reviewers piloted the
use of the assessment tools by independently evaluating
individual websites on NMSC to discuss potential difficulties
or points of disagreement and resolve questions. The degree of
agreement between all 3 reviewers for the final assessment was
quantified by an interrater agreement analysis.
Furthermore, the readability of individual websites, as well as
the visibility and popularity of the domains, was determined by
using established calculating Web-based tools. The baseline
information was extracted to an internally piloted data extraction
sheet using Microsoft Excel 2010. The German melanoma
guideline [26] was used as reference standard to check the
scientific accuracy of a websites’ content.
Quality of Information Assessment
The DISCERN tool (discern.de) is commonly used to assess
the quality of information on cancer [20,24,27] and was
developed for use by laypersons [28]. It consists of 16 items to
review (1) a publication’s transparency (items 1-8); (2) content
(items 9-15); and (3) to give an intuitive assessment summary
(item 16). Items are scored on a 5-point scale ranging from 1
(“criterion is not met at all”) to 5 (“criterion is fully met”). An
overall score of 80 and a summary mean score of 5, respectively,
corresponds to the high quality of a publication (Table 1).
In addition, the presence of a health information quality
certification, such as HONcode from the Health On the Net
Foundation, Public Health Foundation (German: Stiftung
Gesundheit) certificate, or the certificate from afgis (German:
Aktionsforum Gesundheitsinformationssystem e.V.), was
documented for each domain as well. Quality certifications on
health topics are used to indicate that a domain meets particular
quality criteria (eg, for transparency, reliability, and funding)
and are usually awarded by charitable associations.
Assessment of Usability and Reliability
LIDA is a validation tool for health care websites. It contains
41 items [29] for the assessment of the accessibility, usability,
and reliability of domains on health topics. Each item can be
rated with a score of 0 (“never”), 1 (“sometimes”), 2 (“mostly”),
or 3 (“always”). We only assessed the domains’usability (items
7-24 assessing the clarity of information, consistency of the
domain design, the presence of effective browsing and search
functions, and the presence of media) and reliability (items
25-41, assessing the domain update frequency, conflicts of
interest, the methodology of the content production, and the
accuracy of content). As we excluded websites with restricted
access and also because of the unavailability of the basic
corresponding LIDA category during our assessment, we
decided to leave the category accessibility out. The overall LIDA
score was calculated as a sum of the 2 mentioned categories,
resulting in a maximum score of 81.
Assessment of Understandability and Actionability
The Patient Education Materials Assessment Tool (PEMAT)
[30,31] was used to assess the individual websites’
understandability. The understandability part comprises 17
items that cover content, word choice and style, numbers,
structure, layout and design, and the use of visual aids. Another
part covers actionability by 7 items. Each item can be scored
as 0 (“disagree”), 1 (“agree”), or N/A (“not applicable”). Then,
percentages of fulfilled items are calculated. The higher the
value, the more understandability elements are applied on a
website.
Table 1. Overview of assessment tools.
Interpretation of resultsScore rangeLevel of analysisTool usedCategory assessed
Higher values indicate higher quality1-80Individual websitesDISCERNQuality
Presence or
absence
DomainsCheck for the Presence
of Quality certificates
Higher values indicate higher validity0-81DomainsLIDAValidity
Higher values indicate better usability0-54Usability
Higher values indicate higher reliability0-27Reliability
Higher percentage indicate higher under-
standability
0%-100%Individual websitesPEMATaUnderstandability
Higher values indicate better readability
<20 very low,
21-40 low,
41-60 average,
>60 easy
<0 to >60Individual websitesFRESbReadability
Higher values indicate higher visibility0-maxDomainsSISXTRIXVisibility
Lower values indicate better popularity rank1-maxDomainsALEXAPopularity
aPMAT: Patient Education Materials Assessment Tool.
bFRES: Flesch Reading Ease Score.
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Readability Analysis
Since the websites under investigation are accessible for
laypersons and patients with melanoma, we evaluated whether
they provide information in an appropriate readability level and
whether they cover the general public and patients’ readability
needs. Consistent with Azer et al [20], we analyzed a sample
of 200-500 words or 4-5 sentences if the information was
presented in up to 10 sentences. We then calculated the Flesch
Reading Ease score (FRES) by using a Web-based tool
adaptation for German texts [32] to determine the readability
of individual websites. If the text was >10 sentences, we
randomly extracted 4-5 connected sentences and 200-500 words,
respectively. The score was calculated by using a formula that
takes into account the word and sentence length, as well as
characters and syllables per word, resulting in an absolute score
that expresses the readability of a text ranging from <20 (very
difficult), 21-30 (difficult), 31-40 (fairly difficult), 41-60
(standard), 61-70 (fairly easy), 71-80 (easy), and >80 (very
easy). Owing to the FRES formula, it is possible that negative
values may be results of the calculation, if, for example, sentence
or words are very long:
FRES=206,835−84.6×average length of words (number of
syllables)−1015×average length of sentences (number of words).
Popularity and Visibility Analysis
In order to have a reference to a domain’s popularity and
visibility, the ALEXA traffic tool [33] and the SISTRX tool
[34] were used, respectively. We determined the domains’
ALEXA traffic rank in Germany, which is calculated through
a combination of average daily visitors and pageviews on this
domain over the past 3 months, that is, the domain with the
highest combination is rated as number one. In addition, we
estimated the daily pageviews per visitor and the time users
spent on the domain. The SISTRIX visibility index is a measure
of a domain’s discoverability within the search results in Google.
The higher the value, the more visitors browse the domain.
Statistical Analysis
Statistical analyses were conducted by using SPSS (IBM SPSS
Statistics version 24, IBM Corporation, Armonk, NY, USA).
Descriptive analyses included mean (SD) or median and
interquartile ranges (IQR). Subgroup differences were explored
by means of the t test or U test and by one-factor analysis of
variance or the Kruskal–Wallis test. Statistical significance was
set at P ≤.05. The interrater agreement of the 3 reviewers was
determined using the intraclass correlation coefficient, as well
as by determining the interitem correlations r between the
individual reviewers.
Results
Identification of Eligible Websites
Our initial search in Google, Yahoo, and Bing identified 480
individual websites.
Using a multistep process, we screened the 480 websites for
duplicates and checked them for accordance with our eligibility
criteria. Multimedia Appendix 1 presents the detailed
identification process of eligible websites. Finally, 45 individual
websites provided by 30 domains met our eligibility criteria
and were considered for the assessment.
Grouping of Websites
Of 45 individual websites considered, 6 could be assigned to
pharmaceutical companies, 4 to a noncommercial provider, 13
to medical science providers, 11 to the general public press, 7
to commercial health information services, 2 to Wikipedia, 1
to a hospital, and 1 to a health professional. Multimedia
Appendix 2 lists all analyzed websites.
Baseline Information of the Websites
The individual websites were published between 2007 and 2017
with 44% (20/45) published in 2017 and 56% (25/45) in the
years before. The oldest websites were provided by
Pharmazeutische Zeitung (2007) and the University Hospital
of Ulm (2008; Multimedia Appendix 2; #11 and #26).
Two-thirds (n=30) provided information on immunotherapy of
melanoma and one-third (n=15) reported on immunotherapy in
cancer, including melanoma.
Quality of Information
Presence of Quality Certification
The domain krebsgesellschaft.de had a HONcode and an afgis
quality certificate, and the domain apotheken-umschau.de
displayed an afgis certificate, as well as a certificate of the
Public Health Foundation [Stiftung Gesundheit] (Multimedia
Appendix 2; #2 and #5). The other domains had no certificate.
DISCERN Results
Out of a total of 80 points, the 45 individual websites scored
between 35 and 63 points. The mean DISCERN scores ranged
from 2.1 to 3.7 points, indicating a medium–low to
medium–high quality. Most score deductions were because of
lacking information on nontreatment (item 12), on the potential
impact of treatment on the patients’ quality of life (item 13) and
the lack of information on scientifically uncertain aspects of
treatment (item 8; Multimedia Appendix 3). The lowest
DISCERN score was obtained from the website medecon.ruhr
(35 points), and the highest score from wikipedia.org and
uniklinik-ulm.de (63 points each; Multimedia Appendix 2; #22
and #8).
Usability and Reliability—LIDA Results
The 30 domains scored between 39 and 67 points (maximum
of 81 points possible). The assessment by LIDA and the separate
analysis of the usability and reliability sections indicated that
the usability criteria (74%; mean (SD): 40 (2.0) out of 54 points)
were more frequently fulfilled than the reliability criteria (38%;
10 (1.6) out of 27 points; Multimedia Appendix 4; Figure 1).
In particular, the currency and conflicts of interest criteria were
least met (Multimedia Appendix 5). Medecon.ruhr and
scinexx.de were the domains that received the lowest overall
LIDA scores (39 points each), aerzteblatt.de and
krebsgesellschaft.de were rated highest (67 and 66 points;
Multimedia Appendix 2; #22, #18, #1, and #2).
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Figure 1. Quality, usability, reliability, understandability, and readability of 45 websites providing information on melanoma immunotherapy. Box,
lower line: quartile Q1 (25% quantile), middle line: median, upper line: Q3 (75% quantile); aerials, highest values. PEMAT: Patient Education Materials
Assessment Tool; FRES: Flesch Reading Ease Score.
Understandability and Actionability—PEMAT Results
On average, 69% of the understandability elements were applied
by the 45 websites. The lowest PEMAT score was received
from journalonko.de (34%) and the highest from
uniklinik-ulm.de (94%; Multimedia Appendix 2; #9 and #26).
The reviewers could assess an item of actionability in only 16%
(7/45) of websites, indicating that actionability was nonexistent
in nearly all identified websites.
Readability—Flesch Reading Ease Scores
The median FRES was 14 (IQR: 8.5-28.0), indicating that the
information of at least 50% (23/45) of the 45 websites was very
difficult to read for laypersons. Receiving a FRES of 49, the
most readable text was provided by swr.de, whereas the lowest
FRES was calculated for the text provided by a link from
krebsgesellschaft.de with a score of –15 (Multimedia Appendix
2; #6 and #2).
Interrater Agreement
We determined intraclass correlation coefficients of .831 to
.964, indicating a high overall interrater agreement concerning
the assessment by DISCERN, LIDA, and PEMAT (Multimedia
Appendix 6) [35]. The interitem correlations r varied
between.401 and.974, indicating moderate to a high individual
agreement among the 3 reviewers when assessing the individual
items.
Popularity and Visibility
The majority of users visited the domains almost twice a day
[median, 1.7 (IQR: 1.6-2.2)] and browsed a website between
22 and 350 seconds and 142 seconds on average. The domain
t-online was the most frequently and longest visited of the
domains considered and was ranked the most popular according
to the ALEXA tool. The least popular website considered was
journalonko.de (Multimedia Appendix 2; #9). Wikipedia.de
showed the highest SISTRIX visibility value (Multimedia
Appendix 2; #8). Multimedia Appendix 4 summarizes the results
of the assessments using DISCERN, PEMAT, and LIDA by 3
independent reviewers and the determined FRES, ALEXA
(Germany), and SISTRIX values.
Subgroup Analyses
Differences Between Domains of Different Providers
In addition to significant differences in popularity, visibility
(P=.02), and daily visit values (P=.02), differences between the
websites of different providers were particularly evident from
the readability (P<.001) and understandability scores (P<.001),
indicating that the links of the noncommercial provider had the
lowest readability and general public press the highest
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readability (Multimedia Appendix 7). However, pharmaceutical
companies, hospital or health professional, and Wikipedia were
most keen in applying understandability elements. DISCERN
(between 49 (SD 7) and 62 (SD 1) points; P=.07) and LIDA
(between 46 (SD 4) and 66 points; P=.12) scores were not
significantly different.
Differences Between General Public Domains and
Oncology Expert Domains
Websites addressing the general public had significantly higher
popularity (ALEXA; P<.001) and visibility (SISTRIX) ranks
(P=.001) and were visited longer on average (P=.04) but not
necessarily more often (P=.23) than websites predominantly
addressing or provided by oncology experts. The most visible
and popular oncology expert domains were
pharmazeutische-zeitung.de, aerzteblatt.de, and
krebsgesellschaft.de. Furthermore, the public domains had better
readability (P<.001) and understandability (P=.002; Multimedia
Appendix 8). Significant differences in terms of quality,
usability, and reliability could not be detected (P=.06-.76).
However, the LIDA scores were marginally in favor of oncology
expert domains.
Discussion
Principal Findings and Comparison With Prior Work
The websites that we have systematically identified provided
information on melanoma immunotherapy as the main subject
or reported on aspects of cancer immunotherapy in general.
Nearly half of the identified websites were published in 2017,
and the other half in the years before. The majority of websites
could be assigned to providers of scientific medical information
or the general public press and Wikipedia.
We assessed the quality of the individual website information
as medium–low to medium–high, and we found only 2 website
domains from the health care sector that displayed a quality
certification. These findings are similar to those of Bari et al
[19], who found a low use of quality certificates on German
websites (in 4 out of 21), providing general Web-based
information on melanoma. An explanation for this persisting
low presence of certified websites might be that webmasters
have to register, apply, and—following the acceptance—pay
for certification. For example, to acquire the HONcode
certificate, webmasters recurrently have to apply for
certification. In addition, from the second HONcode
membership, a fee is due [36]. Hence, the awarding process of
such quality certificates proclaiming trustworthiness should be
kept in mind, and either their presence or their absence should
be critically appraised. However, the 2 domains we found
providing quality certificates received the above-average quality
of information, usability and reliability scores, and thereby can
be seen as a kind of certificate affirmation.
Score deductions resulting in an overall mediocre quality of the
websites’ content mainly resulted from incomplete and
sometimes superficial reporting about melanoma
immunotherapy, characterized by missing information on
possible treatment consequences for the patients’ quality of life,
on the consequences of nontreatment, and on unclear scientific
evidence for different aspects of treatment. Conversely, more
effort was made to describe the effects and benefits of treatment;
this is a fairly known problem with Web-based cancer
information [20-22,37-39], which makes reporting one-sided
and, thus, withholds important information for treatment
decision making. However, this may not apply to all websites
considered. Highly variable content and quality of websites
providing general melanoma information have been reported
recently [40].
In terms of content, websites offered to the general public
provided only some aspects of melanoma immunotherapy,
whereas websites offered by and to oncology experts included
more detailed and substantial information. In addition, oncology
expert domains marginally met more reliability and usability
criteria. Overall, the 30 domains demonstrated high usability
but low reliability and even lower readability. The low
readability may be attributed to a frequent application of medical
terms, which are not explained in layperson’s terms. In addition,
sentences were sometimes very long and nested, especially in
oncology expert websites, which makes the readability more
complicated. This pattern of high usability but low reliability
and readability has also been found to be typical for websites
providing cancer information [20,21,24,39], including those
providing information on melanoma [16,19]. It is fundamental
that patients can easily read treatment text and understand the
medical terms to benefit from the information. Furthermore, an
indication of the sources quoted and their recency should
routinely be provided on a website to enhance reliability and
trustworthiness. Another problem that should also be addressed
in this context is that among the websites published before 2017,
there were websites offering information dating back to 2007.
As immunotherapy is such a novel innovation and because a
lot of progress has been evolved since the approval for
melanoma treatment with immune checkpoint-inhibiting agents,
such as ipilimumab in 2011, the content of such old websites
is questionable and unreliable.
In general, and if appropriate, the identified websites showed
good efforts to make their contents understandable by applying
various visual aids and supportive structuring elements (eg,
illustrations, paragraphs, simple numbers, and short sections of
texts). However, we found very few elements of actionability.
In this regard, the most visible German websites on melanoma
immunotherapy were in line with other patient education
materials that were previously assessed by the same tool [41,42].
However, the application of more elements of actionability and
interactivity (eg, checklists, videos, and webinars) may facilitate
the users’ handling and understanding of difficult website
content and is highly recommended.
Overall, we found that websites that addressed the general public
were superior in terms of the popularity and visibility compared
with oncology expert domains. They applied more elements to
support the understandability and their information provided
on immunotherapy was easier to read for laypersons but more
superficial in terms of the content. However, we found no
discrepancy between the visibility and quality of websites, as
this was the case in a previous study on German Web-based
cancer information [39].
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Strengths
To date, no work has been published with a comprehensive and
thorough assessment of the most visible German websites
providing information on melanoma immunotherapy. Our results
updated the currently available evidence on the Web-based
melanoma information quality. Three reviewers have
independently assessed the websites using a variety of validated
instruments, yielding an overall good interrater agreement. We
have not only assessed the websites subjectively (eg, by using
tools like DISCERN, PEMAT, or LIDA) but also evaluated
them objectively by using tools like FRES, SISTRIX, or
ALEXA, which measure the values quantitatively. As
immunotherapy is such a novel treatment approach and given
its complexity, a comprehensive assessment of the most visible
websites addressing this topic is of high relevance for both
patients and physicians.
Furthermore, 2 researchers have searched the search engines
Google, Bing, and Yahoo because these websites are searched
from the most patients and the public for general cancer
information [12-15]. In addition, it is interesting to note that the
2 researchers were at different geographical locations of
Germany when searching the 3 search engines. Hence, we might
have identified a full overview on websites because of different
GPS data affecting the algorithms of the search engines.
Therefore, our identified websites might be more
comprehensive.
Limitations
We are aware that this study has some limitations. First, the
websites identified represent only a snapshot of the time when
we searched the 3 search engines in July 2017. Bearing in mind
that immunotherapy is a quite novel approach with a lot of
ongoing progress involved and considering the fast-moving
nature of the internet, one might not identify the identical
websites as we identified. However, we are confident that the
majority of websites will still be available at a later time.
Second, we might have either overestimated or underestimated
FRES values, as we only extracted a sample of 200-500 words
(or 4-5 sentences) to determine the score. It may be possible
that the calculated value might differ when using the entire
number of words available on the website. However, regarding
the consistency, we have stuck to our predefined number of
words. Third, we did not include websites of restricted access
(eg, asking for log-in). Therefore, we might have failed to
identify further websites that were only available when having
access. Hence, the list of identified websites might be
incomplete. However, we believe that patients with melanoma
would not consider those websites and would rather acquire
information from easily-accessible websites. Finally, the
DISCERN, LIDA, and PEMAT assessment was a result of
subjectivity introduced by the individual perspectives of the 3
reviewers. However, the high interrater agreement suggests that
most of the independently detected deficits were apparent to all
of the reviewers and, thus, may be problematic for others.
Conclusions
In general, German websites on immunotherapy for patients
with melanoma provide inexpensive and easily accessible means
to acquire disease- and treatment-specific information. We found
the most visible among them to be user-friendly and
understandably structured. However, the optimization of the
most visible websites is desirable; in particular, improvement
of the information readability and more provision of
meta-information to increase the reliability. We suggest that
the ideal websites should be a hybrid and should include both
oncology expert parts for completeness, content-related integrity,
and details, as well as general public press parts for the visibility
and comprehensibility to be beneficial for more patients.
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